Hyderabad-based gynaecologist completes over 1,000 robotic surgeries
A significant milestone has been achieved in the field of gynecological surgery at Apollo Hospitals in Hyderabad. Dr. Rooma Sinha, a Senior Consultant in Gynaecology and Robotic Surgery, has successfully completed over 1,000 robotic procedures for benign gynecological conditions. This accomplishment is a testament to her exceptional skill and expertise in the field, and places her among a select few surgeons in the world to have reached this milestone.
Dr. Rooma Sinha’s achievement is not only a personal milestone but also a significant step forward for women’s healthcare in India. Millions of women in the country struggle with gynecological issues that affect their well-being and fertility, and Dr. Sinha’s work has helped to restore dignity and health to thousands of them. Each robotic procedure performed by Dr. Sinha has been a step towards improving the lives of these women, and her dedication to her work has earned her the trust of her patients and the respect of her peers.
According to Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, Dr. Sinha’s achievement represents the precision and innovation of robotic surgery, which has made it possible to treat complex gynecological conditions with greater accuracy and minimal invasiveness. Dr. Reddy praised Dr. Sinha’s accomplishment, saying that it reflects the strength of the institution and its commitment to providing world-class healthcare to its patients.
Dr. Sinha’s work has significant implications for women’s healthcare in India, where gynecological issues are often overlooked or undertreated. Her achievement highlights the importance of investing in women’s health and the need for more specialized care and treatment options for gynecological conditions. As Dr. Sinha continues to push the boundaries of what is possible with robotic surgery, her work is likely to inspire other surgeons and healthcare professionals to follow in her footsteps, ultimately leading to better health outcomes for women everywhere.
Pfizer’s $15 Billion Acquisition Fund: What’s Next After Danuglipron Setback? – Insights from Baptista Research on Smartkarma
Pfizer, one of the world’s largest pharmaceutical companies, has amassed a significant war chest of approximately $15 billion, sparking speculation about its potential acquisition targets. The company’s recent setback with Danuglipron, a potential treatment for NASH (non-alcoholic steatohepatitis), has led to increased expectations that Pfizer will make a significant acquisition to bolster its pipeline.
The failure of Danuglipron has left a void in Pfizer’s pipeline, particularly in the NASH treatment space. The company had high hopes for the drug, which was expected to generate significant revenue. With the setback, Pfizer is now under pressure to find alternative ways to drive growth and revenue.
Pfizer’s $15 billion war chest provides the company with the financial flexibility to pursue strategic acquisitions. The company has a history of making significant deals, including its $68 billion acquisition of Wyeth in 2009 and its $14 billion acquisition of Medivation in 2016.
Potential acquisition targets for Pfizer include companies with promising pipeline assets, particularly in areas such as oncology, immunology, and rare diseases. Some potential targets could include:
* Biotech companies with innovative therapies in early-stage development
* Smaller pharmaceutical companies with established products and pipelines
* Companies with expertise in emerging technologies, such as gene editing or cell therapy
Pfizer’s acquisition strategy is likely to focus on bolt-on deals that complement its existing portfolio and pipeline. The company may also consider larger, more transformative deals that could significantly enhance its growth prospects.
Some potential acquisition targets that have been speculated about include:
* Gilead Sciences, a leading player in the HIV and hepatitis C markets
* Biogen, a biotechnology company with a strong portfolio of neuroscience and immunology assets
* Incyte, a biopharmaceutical company with a focus on oncology and inflammation
While Pfizer’s acquisition plans are uncertain, the company’s significant war chest and pressure to drive growth make it likely that a major deal will be announced in the near future. As the pharmaceutical industry continues to evolve, Pfizer’s ability to adapt and innovate through strategic acquisitions will be crucial to its long-term success.
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth is driven by increasing demand for pharmaceuticals, innovation, and the presence of key players in the market.
The report provides a comprehensive analysis of the India Active Pharmaceutical Ingredients market, including market size, revenue, production, and CAGR. It also highlights the competitive landscape, with key players such as Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Cipla, and Sun Pharmaceutical Industries. The report provides a detailed review of major players, covering their financials, product benchmarking, and competitive strategies.
The market is segmented by manufacturer, synthesis type, drug type, application, product type, and formulation. The report also analyzes the geographical landscape of the market, with a focus on North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
The report identifies key drivers and trends in the market, including technological advancements, regulatory and policy shifts, and emerging industry trends. It also highlights the opportunities and challenges in the market, including supply chain issues and evolving consumer behavior.
The report provides actionable insights and quantitative analysis of market segments, trends, estimations, and dynamics. It also includes Porter’s Five Forces analysis for strategic decision-making and segmentation analysis to identify market opportunities.
The key benefits of the report include:
* Quantitative analysis of market segments, trends, estimations, and dynamics
* Insights into key drivers, restraints, and opportunities
* Porter’s Five Forces analysis for strategic decision-making
* Segmentation analysis to identify market opportunities
* Revenue mapping of major countries by region
* Benchmarking and positioning of market players
* Analysis of regional and global trends, key players, and growth strategies
The report is a valuable resource for industry leaders, investors, and decision-makers, providing a comprehensive and detailed analysis of the India Active Pharmaceutical Ingredients market. It is available for purchase, with a 25% discount for a limited time.
Cipla Limited and its division EMEU, have been honoured at the prestigious Healthcare Asia Pharma Awards 2025.
Cipla EMEU and Cipla Limited have been recognized at the Healthcare Asia Pharma Awards 2025 for their innovative initiatives. Cipla EMEU received the ESG Program of the Year – India award for its Ahead & Apart campaign, which promotes sustainable practices in the healthcare ecosystem. The campaign has three core strategies: communication, certification, and sustainable reminders, and has already engaged over 27,000 healthcare professionals (HCPs) across seven countries. The initiative aims to encourage the adoption of Environmental, Social, and Governance (ESG) practices and has earned several achievements, including the prestigious Zero Waste to Landfill Certification.
On the other hand, Cipla Limited received the Most Differentiated Service of the Year – India award for its Breathefree Digital Educator initiative. This platform provides personalized and tech-enabled guidance to patients on how to use their inhalers correctly, addressing the critical barrier to effective treatment in respiratory healthcare. Patients can access the platform by scanning a QR code on their inhaler packaging, which directs them to a live video consultation with a healthcare professional. The platform tracks patient engagement and provides valuable insights to refine educational strategies.
Both initiatives demonstrate the companies’ commitment to innovation and excellence in the pharmaceutical industry. The Ahead & Apart campaign strengthens Cipla’s reputation as a global sustainability leader, while the Breathefree Digital Educator initiative delivers real-world impact by helping patients breathe better and live healthier lives. The Healthcare Asia Pharma Awards recognizes companies in Asia that have redefined pharmaceutical excellence and gives recognition to game-changers and visionaries who possess unwavering commitment to innovation and excellence.
The awards are presented by Healthcare Asia Magazine, and the full list of winners can be viewed on their website. The magazine also invites companies to join the 2026 awards programme and be recognized for their innovative initiatives that have enhanced their business and made remarkable contributions to the pharmaceutical industry. The recognition of Cipla EMEU and Cipla Limited’s initiatives serves as a testament to their dedication to a healthier and greener future, and their commitment to making a positive impact in the lives of patients and healthcare professionals alike.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.